A Multiple Dose Study in Healthy Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970
Latest Information Update: 03 May 2022
Price :
$35 *
At a glance
- Drugs Orforglipron (Primary) ; Esomeprazole
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 25 Apr 2022 Status changed from active, no longer recruiting to completed.
- 22 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 20 Dec 2021 Planned number of patients changed from 24 to 26.